Application of recombination FN polypeptide in preparing medicine for treating severe infectious diseases such as septicemia

Abstract

The invention discloses an N-terminal heparin binding domain polypeptide and a C-terminal binding domain polypeptide of a recombinant fibronectin. The N-terminal heparin binding domain polypeptide consists of five I-type homologous structures of the N-terminal of a FN molecule, including 237 aminophenols, which are from Ser46 to Gly282. A DNA sequence which codes the polypeptide is from 403bp to 1113bp with a length of 711bp. A FCR amplified fragment length is 741bp; a fragment length after double digestion is 729bp. A polypeptide molecular weight, which is expressed by barm, is 28.52kDa. The C-terminal heparin binding domain polypeptide consists of three III-type homologous structures of the FN molecule, including 272 aminophenols, which are from Tyr1720 to Tyr1991. The DNA sequence which codes the polypeptide is from 5428bp to 6244bp with a length of 816bp. The FCR amplified fragment length is 835bp; the fragment length after double digestion is 828bp. The polypeptide molecular weight, which is expressed by barm, is 36.09kDa. The invention is applied to medicine preparations for a serious infection of septicemia, a hemorrhage of thrombocytopenia and a disseminated intravascular coagulation.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to the preparation of recombinant FN heparin binding domain polypeptide and its application in medicines for severe infection such as sepsis, thrombocytopenia bleeding and disseminated intravascular coagulation. Background technique: [0002] Fibronectin, fibronectin, hereinafter referred to as FN; recombinant fibronectin N-terminal heparin-binding domain polypeptide, containing 237 amino acids, molecular weight 29kDa, referred to as rhFNHN-29, recombinant fibronectin C-terminal heparin-binding domain polypeptide, containing 272 amino acids , with a molecular weight of 36kDa, referred to as rhFNHC-36; fibronectin heparin-binding domain I, namely the fibronectin N-terminal heparin-binding domain, referred to as HepI; fibronectin heparin-binding domain II, namely the fibronectin C-terminal heparin-binding domain, referred to as HepII; disseminated intravascular coagulation, Disseminated Intra...

AI Technical Summary

Problems solved by technology

The application of the heparin-binding domain polypeptide in the molecular structure of FN to study its effect on mouse sepsis and DIC models has not been reported at home and abroad

Images